Literature DB >> 7500912

Intact antigen presentation for Epstein-Barr virus (EBV)-specific CTL by a lymphoblastoid cell line established from a patient with severe chronic active EBV infection.

H Kimura1, I Tsuge, S Imai, M Yamamoto, K Kuzushima, T Osato, T Morishima.   

Abstract

Severe chronic active Epstein-Barr virus (EBV) infection is a lymphoproliferative disease characterized by extremely high antibody titers to EBV, fever, lymphadenopathy, hepatosplenomegaly, and pancytopenia, without any prior immunological abnormality. A spontaneous lymphoblastoid cell line was established from a 4-year-old boy with severe chronic active EBV infection. Immunofluorescence and Western blotting analyses showed that the cell line was of B cell origin and expressed Epstein-Barr nuclear antigens 1, 2 3a, 3b and 3c, and latent membrane protein 1, which are reported to be targets for EBV-specific cytotoxic T lymphocytes (CTL). The cytotoxicity of peripheral blood mononuclear cells derived from the patient and his HLA-identical sister was assayed against the cell line. The cell line was recognized and killed by anti-EBV CTL derived from the HLA-identical sister, but the patient's peripheral blood mononuclear cells had no cytotoxicity. We conclude that antigen presentation in the EBV-infected cells from the patient is intact and sufficient for generation of an EBV-specific CTL response. These observations suggest that severe chronic active EBV infection may not be caused by impaired EBV-antigen presentation of the infected cells but by impaired cellular immune responses to the virus. Our results also suggest the therapeutic possibility that this disease may be treated by adoptive transfer of EBV-specific CTL or bone marrow transplantation from an HLA-matched donor whose immune response to EBV is intact.

Entities:  

Mesh:

Year:  1995        PMID: 7500912     DOI: 10.1007/bf00221388

Source DB:  PubMed          Journal:  Med Microbiol Immunol        ISSN: 0300-8584            Impact factor:   3.402


  31 in total

1.  Human immunodeficiency virus genetic variation that can escape cytotoxic T cell recognition.

Authors:  R E Phillips; S Rowland-Jones; D F Nixon; F M Gotch; J P Edwards; A O Ogunlesi; J G Elvin; J A Rothbard; C R Bangham; C R Rizza
Journal:  Nature       Date:  1991-12-12       Impact factor: 49.962

2.  Biomolecular analysis of a defective nontransforming Epstein-Barr virus (EBV) from a patient with chronic active EBV infection.

Authors:  C Alfieri; J H Joncas
Journal:  J Virol       Date:  1987-10       Impact factor: 5.103

3.  Chronic Epstein-Barr virus infection associated with fever and interstitial pneumonitis. Clinical and serologic features and response to antiviral chemotherapy.

Authors:  R T Schooley; R W Carey; G Miller; W Henle; R Eastman; E J Mark; K Kenyon; E O Wheeler; R H Rubin
Journal:  Ann Intern Med       Date:  1986-05       Impact factor: 25.391

4.  Severe chronic EBV infection associated with specific EBV immunodeficiency and an EBNA+ T-cell lymphoma containing linear, EBV DNA.

Authors:  V R Bonagura; B Z Katz; B L Edwards; D J Valacer; P Nisen; E Gloster; R Mir; P Lanzkowsky
Journal:  Clin Immunol Immunopathol       Date:  1990-10

5.  CD3-negative lymphoproliferative disease of granular lymphocytes containing Epstein-Barr viral DNA.

Authors:  K Kawa-Ha; S Ishihara; T Ninomiya; K Yumura-Yagi; J Hara; F Murayama; A Tawa; K Hirai
Journal:  J Clin Invest       Date:  1989-07       Impact factor: 14.808

6.  Heterogeneity of immune defects in three children with a chronic active Epstein-Barr virus infection.

Authors:  W Kuis; J J Roord; B J Zegers; A B Rickinson; J G Kapsenberg; H The; J W Stoop
Journal:  J Clin Immunol       Date:  1985-11       Impact factor: 8.317

7.  T-cell lymphomas containing Epstein-Barr viral DNA in patients with chronic Epstein-Barr virus infections.

Authors:  J F Jones; S Shurin; C Abramowsky; R R Tubbs; C G Sciotto; R Wahl; J Sands; D Gottman; B Z Katz; J Sklar
Journal:  N Engl J Med       Date:  1988-03-24       Impact factor: 91.245

8.  Epstein-Barr virus infection rapidly progressing to monoclonal lymphoproliferative disease in a child with selective immunodeficiency.

Authors:  V Schuster; H W Kreth; H K Müller-Hermelink; H I Huppertz; A C Feller; D Neumann-Haefelin; H Wiegand; N Müller-Lantzsch
Journal:  Eur J Pediatr       Date:  1990-11       Impact factor: 3.183

9.  Differences in B cell growth phenotype reflect novel patterns of Epstein-Barr virus latent gene expression in Burkitt's lymphoma cells.

Authors:  M Rowe; D T Rowe; C D Gregory; L S Young; P J Farrell; H Rupani; A B Rickinson
Journal:  EMBO J       Date:  1987-09       Impact factor: 11.598

10.  Localization of Epstein-Barr virus cytotoxic T cell epitopes using recombinant vaccinia: implications for vaccine development.

Authors:  R Khanna; S R Burrows; M G Kurilla; C A Jacob; I S Misko; T B Sculley; E Kieff; D J Moss
Journal:  J Exp Med       Date:  1992-07-01       Impact factor: 14.307

View more
  5 in total

1.  Successful reduced-intensity stem cell transplantation with cord blood for a poor-prognosis adult with refractory chronic active epstein-barr virus infection.

Authors:  Masao Nakagawa; Satoshi Hashino; Mutsumi Takahata; Takahito Kawamura; Fumie Fujisawa; Kaoru Kahata; Takeshi Kondo; Masahiro Imamura; Sachiko Ando; Masahiro Asaka
Journal:  Int J Hematol       Date:  2007-06       Impact factor: 2.490

2.  Characterization of Epstein-Barr virus (EBV)-infected natural killer (NK) cell proliferation in patients with severe mosquito allergy; establishment of an IL-2-dependent NK-like cell line.

Authors:  I Tsuge; T Morishima; M Morita; H Kimura; K Kuzushima; H Matsuoka
Journal:  Clin Exp Immunol       Date:  1999-03       Impact factor: 4.330

3.  Clinical effects of infusing anti-Epstein-Barr virus (EBV)-specific cytotoxic T-lymphocytes into patients with severe chronic active EBV infection.

Authors:  Masao Hagihara; Takahide Tsuchiya; Osamu Hyodo; Yoko Ueda; Kei Tazume; Aya Masui; Ayako Kanemura; Fumiaki Yoshiba; Shinji Takashimizu; Shohei Matzusaki; Shunichi Kato; Tomomitsu Hotta
Journal:  Int J Hematol       Date:  2003-07       Impact factor: 2.490

4.  Quantitative analysis of Epstein-Barr virus load by using a real-time PCR assay.

Authors:  H Kimura; M Morita; Y Yabuta; K Kuzushima; K Kato; S Kojima; T Matsuyama; T Morishima
Journal:  J Clin Microbiol       Date:  1999-01       Impact factor: 5.948

Review 5.  Chronic Active Epstein-Barr Virus Disease.

Authors:  Hiroshi Kimura; Jeffrey I Cohen
Journal:  Front Immunol       Date:  2017-12-22       Impact factor: 7.561

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.